125 related articles for article (PubMed ID: 15084120)
1. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
Lepper ER; Ng SS; Gütschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD
J Med Chem; 2004 Apr; 47(9):2219-27. PubMed ID: 15084120
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
[TBL] [Abstract][Full Text] [Related]
3. Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFalpha modulators.
Avila CM; Romeiro NC; da Silva GM; Sant'Anna CM; Barreiro EJ; Fraga CA
Bioorg Med Chem; 2006 Oct; 14(20):6874-85. PubMed ID: 16843662
[TBL] [Abstract][Full Text] [Related]
4. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Ng SS; Gütschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD
Cancer Res; 2003 Jun; 63(12):3189-94. PubMed ID: 12810647
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR studies of heterocyclic quinones with inhibitory activity on vascular smooth muscle cell proliferation using pharmacophore-based alignment.
Ryu CK; Lee Y; Park SG; You HJ; Lee RY; Lee SY; Choi S
Bioorg Med Chem; 2008 Nov; 16(22):9772-9. PubMed ID: 18930405
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
10. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
11. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
15. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents.
Murugesan V; Prabhakar YS; Katti SB
J Mol Graph Model; 2009 Feb; 27(6):735-43. PubMed ID: 19117780
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
18. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
Pasha FA; Muddassar M; Neaz MM; Cho SJ
J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
